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Abstract: Polyomaviruses are non-enveloped, dsDNA viruses that are common in mammals, 
including humans. All polyomaviruses encode the large T-antigen and small t-antigen 
proteins that share conserved functional domains, comprising binding motifs for the tumor 
suppressors pRb and p53, and for protein phosphatase 2A, respectively. At present,  
13 different human polyomaviruses are known, and for some of them their large T-antigen 
and small t-antigen have been shown to possess oncogenic properties in cell culture and 
animal models, while similar functions are assumed for the large T- and small t-antigen of 
other human polyomaviruses. However, so far the Merkel cell polyomavirus seems to be the 
only human polyomavirus associated with cancer. The large T- and small t-antigen exert 
their tumorigenic effects through classical hallmarks of cancer: inhibiting tumor suppressors, 
activating tumor promoters, preventing apoptosis, inducing angiogenesis and stimulating 
metastasis. This review elaborates on the putative roles of human polyomaviruses in some 
of the emerging hallmarks of cancer. The reciprocal interactions between human 
polyomaviruses and the immune system response are discussed, a plausible role of 
polyomavirus-encoded and polyomavirus-induced microRNA in cancer is described, and the 
effect of polyomaviruses on energy homeostasis and exosomes is explored. Therapeutic 
strategies against these emerging hallmarks of cancer are also suggested.  
Keywords: polyomavirus; microRNA; inflammation; autophagy; glucose; therapy; exosomes 
 
OPEN ACCESS 




Polyomaviruses are naked, circular double-stranded DNA viruses that infect birds and mammals, and 
recently the first fish-associated polyomavirus was described [1,2]. The genome of most polyomaviruses 
is approximately 5000 base-pairs and encodes regulatory proteins and structural proteins. The major 
regulatory proteins are the large tumor antigen (LT-ag) and the small tumor antigen (st-ag), while at least 
two structural proteins (VP1 and VP2) form the capsid. The regulatory proteins are expressed early 
during infection and participate in viral replication and viral transcription, while the structural proteins 
are expressed later in the infection cycle [3]. Many polyomaviruses encode additional regulatory and 
structural proteins (e.g., ALTO, VP3, VP4, agnoprotein) [4–6].  
Studies with mice in the 1950s initiated by Ludwik Gross, and extended by Sarah Stewart and Bernice 
Eddy led to the identification of the first polyomavirus. They showed that a filtrate from a mouse 
leukaemia could cause multiple tumors in new-born mice and later it was demonstrated that these 
multiple tumors were virus-indeed. Hence the virus was referred to as polyomavirus from the Greek 
πολύσ for many and ωµα for tumors (reviewed in [7]). The first primate polyomavirus was isolated in 
1960 [8]. This virus, Simian virus 40 (SV40), was shown to transform cells, including human cells, to 
induce tumors in animal models, and to be present in human cancers. The oncogenic potential of SV40 
primarily depends on its LT-ag, which can bind the tumor suppressor proteins p53 and pRb, interfere 
with DNA repair, apoptosis, cellular transcription, protein degradation, telomerase activity, immune- and 
inflammatory responses, and stimulate angiogenesis and cell migration. SV40 st-ag can contribute to 
transformation by inactivating protein phosphatase 2A [9,10]. Besides SV40 and murine polyomavirus, 
other non-human polyomavirus such as hamster polyomavirus, lymphotropic polyomavirus, and simian 
agent 12 were shown to possess oncogenic properties in cell cultures or animal models [11–13]. However, 
the oncogenic role of these viruses in their natural host is unclear. In fact, only one mammalian 
polyomavirus seems to be firmly associated with cancer in its genuine host. Raccoon polyomavirus 
(RacPyV) was first identified in tumors of frontal lobes and olfactory tracts from raccoons. Ten out of 
52 (19%) raccoons had brain tumors within the cranial portion of their frontal lobe(s), and all tumors 
contained RacPyV DNA, though not tissues from 20 unaffected animals. RacPyV genome was episomal 
in all tumors tested [14]. One case of hamster polyomavirus-induced lymphoma in a hamster outside of 
the laboratory environment has been described [15], while two novel mammalian polyomaviruses have 
been isolated from benign tumors. A polyomavirus was isolated from fibropapilloma on the tongue of a 
sea lion, and the complete genome of another polyomavirus was amplified in a biopsy from a fibroma 
on the trunk of an African elephant [16,17]. Further studies are required to assess whether these 
mammals are the genuine host, and whether these polyomaviruses are the causal infectious agent of such 
hyperplastic fibrous tissue in their natural host. 
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In contrast to mammalian polyomaviruses, bird polyomaviruses do not seem to induce tumors. 
Despite a similar genetic organization to that of mammalian polyomavirus, their LT-ag lacks homologies 
to the p53 binding sequences of mammalian polyomavirus and not all avian polyomavirus LT-ag possess 
the consensus sequence LXCXE required for pRb binding [18]. 
2. Human Polyomaviruses and Cancer  
The first two human polyomavirus viruses were isolated in 1971, and were named after the initials of 
the patient in which the virus was found: the BK virus (BKPyV) and the JC virus (JCPyV) [19,20].  
Both BKPyV and JCPyV possess a genomic organization that resembles SV40 more than the murine 
polyomavirus. The former three viruses lack the middle T-antigen that is encoded by the murine 
polyomavirus, but have an additional late gene referred to as the agnogene [3]. Because the genomic 
organization of SV40 displays a higher functional and sequence similarity with the BKPyV and JCPyV, 
SV40 became the polyomavirus model system for unveiling the oncogenic mechanisms of this  
family [21,22]. Since 2007, 11 novel human polyomaviruses have been described: KIPyV, WUPyV, 
Merkel cell PyV (MCPyV), HPyV6, HPyV7, Trichodysplasia spinulosa-associated PyV (TSPyV), 
HPyV9, HPyV10 (and the isolates MW and MX), STLPyV, HPyV12, and NJPyV-2013 [23–35]. The 
seroprevalence of the different human polyomavirus ranges from ~25% to ~100% depending on the 
virus. The high seropositivity therefore demonstrates that these viruses are common in the adult human 
population [36–38].  
Whereas the oncogenic properties of BKPyV, JCPyV and MCPyV in cell culture and animal models 
are well-documented [39–42], only MCPyV seems to be associated with cancer in its natural host. 
Approximately 80% of Merkel cell carcinoma tumors are positive for the MCPyV genome, which is 
typically integrated and encodes a truncated form of LT-ag [43]. BKPyV and JCPyV DNA, RNA and 
proteins have been detected in several tumor tissues, but are also often present in control non-malignant 
tissues [44–46]. Hence, a causal role for these viruses in human cancers remains controversial, although 
the presence of BKPyV may increase the risk of the development of renal and prostate cancer, while JCPyV 
may be associated with colorectal cancer and CNS tumors [47–50]. Polyomavirus-associated colorectal 
cancer may be due to other polyomaviruses present in meat as suggested by Harald zur Hausen [51]. Recent 
analyses of beef samples have identified several bovine polyomaviruses related to the human polyomaviruses 
MCPyV, HPyV 6, HPyV7 or other animal polyomaviruses including fruit bat polyomavirus, RacPyV 
and chimpanzee polyomavirus [52,53]. It remains to be established whether these viruses can be detected 
in human colorectal biopsies. The possible association of the other human polyomaviruses with cancer 
has been scarcely examined, and in only few cases was viral DNA or protein detected in tumor tissue 
(Table 1). Based on our present knowledge, convincing proof of their role in these cancers is lacking. 
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Table 1. Prevalence of the novel human polyomaviruses in human cancers. BK virus 
(BKPyV), JC virus (JCPyV), Merkel cell PyV (MCPyV) are not included. 
 Number of samples Method Number of positive samples Comments Reference 








Low viral DNA 
loads, but higher 
for HPyV6 
[54] 
Mucosal melanoma 37 PCR KIPyV: 0 
WUPyV: 0  
HPyV6:0 
HPyV7:0 




Squamous cell carcinoma 63 PCR HPyV6: 2 
HPyV7: 1 
Low viral DNA 
loads 
[56] 
Basal cell carcinoma 50 PCR HPyV6: 1 
HPyV7: 2 
Low viral DNA 
loads 
[56] 
Melanoma 47 PCR HPyV6: 2 
HPyV7: 2 
Low viral DNA 
loads 
[56] 
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Table 1. Cont. 


















38 PCR KIPyV: 0 
WUPyV: 0 
 [60] 
SCC+AK 142 deep 
sequencing 
HPyV6: 1  [61] 
Chronic lymphocytic 
leukaemia 
27 PCR HPyV9: 0  [62] 
Primary cutaneous B-cell 
lymphomas 
(CBCLs) or cutaneous T-
cell lymphomas 
(CTCLs) 








skin tumor associated 
with hair follicles 
? ? TSPyV: 0  [65] 
Lung cancer 20 PCR KIPyV:9  [66] 
CNS tumors 25 PCR KIPyV: 0 
WUPyV: 0 
 [67] 





50 PCR KIPyV: 0 
WUPyV: 0 
 [68] 



















Skin lesions from CTCL 
patients 
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Table 1. Cont. 
 Number of samples Method Number of positive samples Comments Reference 
Blood from CTCL 
patients 










Thymic epithelial tumors 
 
Thymic hyperplasias 









              PCR   FISH      IHC 
HPyV7:   20       23          17 
HPyV6:     0 
 
HPyV7:     8       14            6  
HPyV7:     0 
 [74] 
The cancer biology of BKPyV, JCPyV and MCPyV has been extensively reviewed by  
others [39,43,45,46,75–77] and is also discussed by others in this special issue on Tumor Viruses. This 
review will focus on novel strategies that human polyomaviruses may use to transform cells. Figure 1 
summarizes the novel mechanisms by which HPyV may contribute to cancer.  
 
Figure 1. Novel mechanisms by which HPyV may contribute to cancer. See text and  
Table 2 for details. 
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3. HPyV and Emerging Hallmarks of Cancer 
3.1. The Immune System and HPyV in Cancer 
Individuals with a dysfunctional immune system are more disposed to diseases, infections and  
(viral-induced) cancers. Moreover, oncoviruses can induce inflammation, which may predispose host 
cells to acquire carcinogenic mutations [78]. In accordance with the cancer immunoediting hypothesis, 
tumor cells need to proficiently traverse separate phases in a sequential order to attain cancer manifestation 
and progression. These phases constitute interactions between the immune system and the cancer cell, 
and include the elimination of newly transformed cells, an equilibrium in which the immune system 
restrains the outgrowth of tumors, and an escape in which the tumor cells are able to circumvent the host 
immune response phases [79–81]. For a virus to induce tumors, they need to circumvent elimination by 
the immune system and to induce alternations in the tumor microenvironment, including in the infected 
cell allowing the virus-transformed cell to progress [82,83]. Because MCPyV is the only HPyV 
associated with cancer, the main focus will be on MCPyV’s interaction with the immune system.  
Epidemiologic data show that patients with T cell dysfunction are at a 5- to 50-fold increased risk of 
developing MCC, thereby indicating the importance of the immune system (reviewed in [83]). However, 
immunocompetent individuals may also develop MCPyV-positive MCC, suggesting that the virus and 
virus-infected cells can avoid elimination by the immune system.  
3.1.1. HPyV and Evasion of the Innate Immune System 
One mechanism by which MCPyV circumvents the immune system is to abate the innate defence 
mechanism. MCPyV LT-ag and st-ag downregulate the Toll-like receptor 9 (TLR9), an important 
receptor of the host innate immune system that senses viral dsDNA in epithelial and MCC cells [84]. 
LT-ag inhibits TLR9 expression by decreasing the mRNA levels of the transcription factor C/EBPβ.  
LT-ag of BKPyV, but not JCPyV, KIPyV and WUPyV, is also able to repress TLR9 expression. 
Interestingly, C/EBPβ has a vital role in regulating IL-6, IL-8, and TNF-α cytokine transcription [85]. 
Moreover, it is also suggested that C/EBPβ has a tumor-suppressive activity by down-regulating CDK2, 
CDK4, and E2F complex activity [86,87]. Thus MCPyV LT-ag mediated suppression of C/EBPβ expression 
may perturb immune responses and provoke cell proliferation. 
3.1.2. Immune Cells in the Microenvironment of MCC 
To investigate inflammatory modulators in MCC required for escaping of the tumor from  
immune surveillance, and to deduce a possible contribution of MCPyV in oncogenesis, several groups 
have examined immune cells and inflammatory mediators virus-positive and virus-negative MCC. 
Differences in immune and inflammatory cells, markers, and gene expression in MCPyV-positive and 
MCPyV-negative MCC tumors are summarized in Table 2. Compared to virus-negative tumors, a higher 
number of infiltrating CD8+ T-cells in MCPyV-positive MCC has been observed [89–91], while  
others group have not detected a relationship with virus status and the number of intratumoral CD8+  
T-cells [92,93]. Other differences in the microenvironment of virus-positive and virus-negative MCC 
include a higher number of CD3+ T-cells, CD20+ B cells, CD16+ natural killer cells, and CD68+, 
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CD69+, CD163+ macrophages [88–90,93–95]. FoxP3+ regulatory T-cells were present in 4/4 LT-ag 
positive MCC, whereas 3/6 LT-ag negative tumors did not contain FoxP3+ regulatory T-cells [93]. 
Table 2. Immune cells and inflammatory mediators in MCPyV-positive and MCPyV-negative 
Merkel cell carcinoma (MCC). 
Component MCPyV-positive versus MCPyV-negative MCC Reference 







- CD16+ natural killer cell 
 







-FoxP3+ regulatory T-cells 
 
 
higher number in MCPyV-positive MCC 
 
high number associated with high LT-ag expression 
higher number in MCPyV-positive MCC 
 
higher number in MCPyV-positive MCC 
 
more common in MCPyV-positive MCC; 
no significant difference between MCPyV-positive and –
negative MCC 
higher number in MCPyV-positive MCC 
 
higher number in MCPyV-positive MCC 
 
































enrichment of transcripts in MCPyV-positive MCC 
enrichment of transcripts in MCPyV-positive MCC 
lacking in CD8+ T-cells 
 
lower levels in MCPyV-positive MCC 
 
higher in MCPyV-positive MCC 
 






















lower in MCPyV-positive MCC 
 
lower in MCPyV-positive MCC 
 
 
reduction in MCPyV st-ag expressing cells MCC13 cells 
compared to virus-negative cells 
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Table 2. Cont. 










-Prokineticin 1 mRNA 
 
-Prokineticin 2 mRNA 
 
reduction in MCPyV st-ag expressing cells MCC13 cells 
compared to virus-negative cells 
reduction in MCPyV st-ag expressing cells MCC13 cells 
compared to virus-negative cells 
reduction in MCPyV st-ag expressing cells MCC13 cells 
compared to virus-negative cells 
reduction in MCPyV st-ag expressing cells MCC13 cells 
compared to virus-negative cells 
higher in MCPyV-negative MCC 
 













Other differentially expressed proteins 
-granzyme B (role in apoptosis) 
 
 




Afanasieve et al. proposed that MCC tumors may prevent the invasion of lymphocytes by a reduction 
of E-selectin-positive vessels within the tumors because the downregulation of E-selectin in human 
squamous cell carcinomas was associated with a restricted entry of T-cells into tumors [100,101]. Of 56 
tested MCC biopsies, approximately half displayed a reduction of E-selectin-positive vessels within the 
tumors compared with vessels in peritumoral areas [102]. However, the association between the presence 
of virus and E-selectin levels was not investigated. 
3.1.3. Changes in Expression of Cell Surface Markers on MCC Cells 
Expression of cell surface markers was performed to determine the functionality of the immune cells. 
These analyses revealed that the expression of MHC-I in MCPyV-positive MCC was significantly lower 
than in virus-negative MCC [96]. Cell-surface MHC-I expression was down-regulated in 84%  
(n = 114) of MCC, and approximately half of the tumors had poor or undetectable MHC-I levels. The 
downregulation of MHC-I expression has been identified as a vital immune evasion strategy used by 
several viruses, including oncoviruses [103–108]. An identical mechanism can be employed by  
MCPyV, but it remains to be determined as to whether viral proteins are implicated in MHC-I  
down-regulation. Tumors that undergo a significant downregulation of MHC-I should become a target 
of natural killer cells. MCC can avoid this by e.g., reducing the expression of NK-activating receptors 
such as natural killer group 2, member D (NKG2D) [109]. Interestingly, BKPyV and JCPyV microRNA 
target ULBP3, which is the ligand of NKG2D (see further), though it is not known whether MCPyV 
microRNA targets ULBP3 or NKG2D. Another surface marker that was differentially expressed on 
MCPyV-positive and negative tumors is the immune-inhibitory ligand programmed death ligand-1  
(PD-L1) [95,97,98]. The major receptor for PD-L1, PD-1 is expressed by activated T lymphocytes, and 
when this receptor is engaged by its ligands PD-L1 it serves to inhibit the T-cell response. PD-L1 may 
be aberrantly expressed by tumor cells and protect against immune attack [110]. The number of  
intra-tumor T-cells is commonly higher in virus-positive MCC than virus-negative MCC, and PD-1 was 
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expressed on a high percentage of MCPyV-positive tumors [95,97,98]. Moreover, approximately 50% 
of MCPyV-positive MCC express PD-L1 on tumor cells, while no expression was detected in  
MCPyV-negative MCC. Hence, the association between PD-1-positive cells and PD-L1 expression in the 
tumor microenvironment seems to create immune resistance by the tumor, thereby allowing the tumor to 
progress [97,98]. The mechanism by which MCPyV provokes the expression of PD-L1 remains to be 
determined, but Lipson and co-workers anticipated that IFN-γ may drive PD-L1 expression, but other 
interleukins such as IL-6, IL-10, IL-17 and IL-21 cannot be excluded. A role for PD-1 positive cells in 
protecting PD-L1-expressing MCC cells is buttressed by observations in a complete or partial regression 
of MCC. The exact mechanism for spontaneous regression is not known, although T-cell-mediated 
response and apoptosis by T-cells has been suggested [111]. The rate of regression of MCPyV-positive 
versus MCPyV-negative MCC has not been evaluated, but complete regression has been reported in a 
76-year old Japanese man with virus-positive MCC [112]. In this patient, only ~3% of the  
tumor-infiltrating T-cells were PD-1 positive, while in three other patients (females, mean age 81.3 years) 
with MCPyV-positive MCC who did not show any regression of the tumor, 18.2%–23.0% of the T-cells 
were of PD-1 positive. This suggests that a reduction of PD-1-positive T-cells may be associated with 
spontaneous tumor regression [112]. Another surface protein that was aberrantly expressed on immune 
cells in the tumor microenvironment was CXCR3 [97]. All CD8+ cells lacked CXCR3, thus indicating 
that these T-cells were functionally compromised. CXCL12 or stromal cell-derived factor 1, a chemokine 
with pleiotropic functions, including the attraction of inflammatory cells [113], was expressed outside 
malignant nodules, but its receptor CXCR4 was expressed by tumor cells, though not on infiltrating 
CD8+ cells. Finally, the cell-surface protein T-cell immunoglobulin and mucin domain-3 (Tim-3), which 
also functions to inhibit T-cell responses, was also upregulated on infiltrating T-cells in MCPyV-positive 
MCC [97]. 
3.1.4. Expression Profile of Genes Associated with the Immune Response in MCC 
Gene expression profile analysis has been applied to identify differentially expressed genes in 
MCPyV-positive and MCPyV-negative MCC. Microarray technology, using >54,000 probes, identified 
1593 genes that were differently (>2-fold) expressed comparing virus-positive and virus-negative  
MCCs [89]. An enrichment of genes associated with the immune response included genes encoding the 
δ and γ chains of CD3, the tyrosine kinase ZAP70, which plays an important role in the T-cell response, 
and the C-region of the µ heavy chain. Another approach compared the transcriptome from cells with an 
inducible expression of MCPyV st-ag with that of control cells, and revealed that the induction of st-ag 
expression resulted in >2-fold reduced transcript levγels of genes associated with the immune response 
such as CCL20, CXCL-9, IL-2, IL-8 and TANK, a negative regulator of TLR signaling. Less CCL20 
and IL-8 were secreted by MCC13 cells expressing MCPyV st-ag compared with virus-negative MCC13 
cells after TNFα stimulation [99]. mRNA profiling of 35 MCC tumors (both MCPyV-positive and 
negative) with favorable prognoses overexpressed genes such as components of cytotoxic granules 
(granzymes A, B, H and K), chemokine CCL19 and chemokine receptor 2, MHC-II and NKG2D [92]. 
The contribution of MCPyV on the expression of these genes cannot be appreciated because the data 
originate from both MCPyV-positive and MCPyV-negative tumors. Gene expression profiling of MCC 
tumor cells showed the lack of expression of IL-2 and IFN-γ, whereas IL-12 was expressed [113]. 
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However, this study was performed before MCPyV was identified, so therefore a role of the virus in 
altered gene expression cannot be deduced. Another study monitored the transcript levels of the 
chemokine-like proteins prokineticin-1 and prokineticin-2, which are involved in angiogenesis, 
inflammation and cancer. MCPyV-positive MCCs had a higher than median prokineticin-2 mRNA 
levels, while virus-negative tumors had a higher than median prokineticin-1 transcript levels [90]. A 
high tumor prokineticin-2 mRNA content was associated with the expression of MCPyV LT-ag. The 
biological relevance of this observation for virus-induced MCC remains to be established. Wheat and 
co-workers observed that the expression of granzyme B, a mediator of apoptosis [114], was rare in MCC 
infiltrating CD8+ cells, hence suggesting that these cytotoxic T cells were functionally compromised [93]. 
3.1.5. Effect of st-ag on the NF-κB Pathway 
The molecular mechanism by which MCPyV may perturb gene expression in virus-positive MCC 
tumor cells is not known, but several of the genes listed in Table 2 (e.g., CXCL9, IL-2, IL-8, MHC-I, 
IκB) are known to be a target for NF-κB [115,116]. Interestingly, MCPyV st-ag was shown to downregulate 
NF-κB-mediated transcription [99]. St-ag-mediated inhibition of the NF-κB pathway seems to require 
an interaction of st-ag with NF-κB essential modulator (NEMO) adaptor protein and protein phosphatases 
2A and 4C. This will prevent IKKα/IIKβ-mediated phosphorylation of IκB, thus leading to a reduced 
nuclear translocation of NF-κB. MCPyV interference with the NF-κB pathway is further sustained by 
the observations that IκB levels were 60% lower in the MCPyV-positive MCC cell line MKL-1 compared 
with MCPyV-negative MCC13 cells, and by a declined expression of NF-κB and NF-κB-associated genes 
in virus-positive MCC compared to virus-negative MCC [99,117]. All these findings indicate that 
MCPyV interferes with the NF-κB pathway, and that MCPyV st-ag may help the virus to evade the host 
antiviral defence and to persist in the infected cell [99]. It is not known whether the st-ag of other HPyV 
has the same property, but residues 95 to 111, which are crucial for the interaction between MCPyV  
st-ag, NEMO and PP2A and PP4C are not conserved [118]. Interestingly, ultraviolet (UV) exposure,  
a risk factor for MCC [119], was shown to stimulate mutations in LT-ag and increase the expression of  
st-ag in the tumor cells [120]. Hence, UV exposure may be a virus-dependent mechanism that promotes 
MCPyV-induced MCC through the aforementioned st-ag:NF-κB interaction.   
3.1.6. Viral Microrna and Evation of the Immune Response  
Another mechanism by which HPyV may affect gene expression is by microRNA. MicroRNAs 
(miRNAs) are small RNAs that can down-regulate protein production by either degrading transcripts or 
inhibiting the translation of mRNA. SV40 miRNA, the first PyV miRNA to be described, was shown to 
reduce cytotoxic T lymphocyte-mediated lysis and IFN-γ release [121], whereas other HPyV seem to 
apply different strategies to escape the immune system. BKPyV, JCPyV and MCPyV miRNA were 
unable to inhibit IFN-induced transcription of the luciferase reporter gene [122], but BKPyV and JCPyV 
miRNAs inhibited the translation of UL16-binding protein 3 (ULBP3) mRNA [123]. ULBP3 is a ligand 
recognized by natural killer group 2, member D (NKG2D) receptor. NKG2D is expressed by NK and 
CD8+ T-cells and binding to ULBP3 triggers killing of the target cell [124]. Consequently, BKPyV- and 
JCPyV-infected cells may escape from NKG2D-mediated killing and circumvent the immune system. 
The proteins PSME3 and PIK3CD/p110δ, which are implicated in immune functions, were predicted to 
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be putative targets for MCPyV miRNA [125]. PSME3 is a subunit of a proteasome responsible for the 
generation of peptides loaded onto MHC I, and PI3KCD plays a unique role in antigen receptor signaling 
by activating T-cells and B-cell proliferation [126–128]. The depletion of these proteins may prevent 
MCPyV infection to be cleared by the immune system, thereby allowing the viral infection to sustain. 
One of the SV40 strain RI257 miRNA targets is α-actinin 4 (ACTN4), a protein that activates the NFκB 
pathway [129]. Stable knockdown of ACTN4 reduces TNFα-mediated induction of NFκB and expression 
of e.g., IL-1β [130]. SV40-RI257I miRNA may therefore interfere with inflammatory responses. The 
3p, and the 5p miRNAs of BKPyV and JCPyV share sequence identity (16 out of 22 nucleotides) with 
SV40-RI257I miRNA [6], but it is not known whether they also target ACTN4. SV40 strain 776 
microRNA was shown to diminish the expression of the Serine/Threonine kinase MST4 in the African 
green monkey kidney epithelial cell line BSC-40, though not in human embryonal kidney 293T  
cells [129]. Interestingly, knockdown of MST4 in mice resulted in an exacerbated inflammation upon 
septic shock [131]. It is not known whether any of the HPyV encodes a miRNA that targets MST4, but 
if so, the following scenario can be imagined: A persistent HPyV infection may result in the depletion 
of MST4, thus causing the aggravation of inflammatory responses and a contribution to malignancy. 
3.2. The Role of HPyV microRNA and HPyV-induced microRNA in Cancer 
Some polyomaviruses have been shown to express viral miRNA, while others may encode a putative 
miRNA [6,132–134]. Although several viral miRNAs have been suggested to play a role in cancer [135], 
a direct implication of HPyV miRNA in cancer is lacking. Because RacPyV and MCPyV are the only 
PyV to so far be associated with cancer in their natural host, the expression of their miRNAs was examined 
in tumors. RacPyV miRNA was among the most abundant miRNAs detectable in RacPyV-associated 
tumors, but was not observed in RacPyV-negative non-tumor raccoon tissue [134]. This stands in 
contrast to MCPyV-positive MCC tumors, in which viral miRNA is only detectable in less than half of 
the tumors tested, and when present, MCPyV miRNA levels were <0.025% of total miRNAs in MCPyV-
positive MCC [125,136]. This observation suggests that MCPyV miRNA is not involved in MCC. 
PyV miRNA can modulate biological activities that can contribute to malignancy such as evading  
the immune system, apoptosis and perturbing cellular gene expression [137,138]. The role of  
HPyV-encoded miRNA in immune evasion was discussed above. PyV miRNAs may also prevent 
apoptosis. MCPyV miRNA targets the host cell protein AMBRA1, which is involved in autophagy and 
apoptosis [139], while mouse PyV miRNA downregulates the pro-apoptotic factor Smad2, resulting in 
a suppression of apoptosis in vivo [140]. Aberrant cellular gene expression may promote neoplastic 
progression, and PyV miRNAs may perturb cellular gene expression by interfering with splicing, thereby 
targeting transcription factors or proteins controlling the activity of transcription factors, or by inducing 
the expression of cellular miRNAs. SV40 miRNA is predicted to target the dual-specificity protein 
phosphatase DUSP8, a negative regulator of the JNK and p38 mitogen-activated protein kinases, 
whereas MCPyV may downregulate the expression of transcription factor RUNX1, the splicing factor 
RBM9/FOX2, as well as the repressor MECP2 [125,129]. Viral infection can induce a unique signature 
of host cell miRNAs, which may contribute to viral pathogenic processes [141]. MiRNAs are initially 
transcribed by RNA polymerase II, and SV40 LT-ag has been shown to interfere with RNA polymerase 
II-dependent transcription [142,143]. Hence, PyV infection may alter the pattern of cellular miRNA 
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expression. However, a common feature shared by all known PyV miRNA is the silencing expression of 
LT-ag so that no effect on cellular miRNA expression is expected [121,122,132,134,144,145]. On the other 
hand, interference with cellular miRNA expression is plausible in MCPyV-positive tumors because MCC 
do express LT-ag [146], and RacPyV-positive tumors also express LT-ag [147]. The effect of LT-ag on 
cellular miRNA expression has not been investigated, but the proteins of the oncovirus HBV, EBV, KSHV 
and HCV help regulate the levels of cellular miRNAs, including oncogenic miRNAs [148–154].  
Xie and co-workers compared miRNA profile in MCPyV-positive and negative MCC. One miRNA 
that was significantly lower expressed in MCPyV-positive MCC compared to MCPyV-negative MCC 
was miR-203. The overexpression of miR-203 in MCPyV-negative MCC inhibited cell growth and 
induced cell cycle arrest [155]. This finding suggests that MCPyV may cause cell proliferation by 
repressing the expression of miR-203, but the exact mechanism by which MCPyV may regulate this 
miRNA remains to be elucidated.   
3.3. Effect of HPyV on Energy Homeostasis 
In healthy cells, glycolysis initiates in the cytoplasm where glucose is metabolized into pyruvate, 
which then enters the mitochondria where it is converted into acetyl-CoA and enters the Krebs’ cycle to 
generate ATP. In cancer cells, a metabolic switch occurs: the suppression of mitochondrial glucose 
oxidation and the upregulation of aerobic breakdown of glucose. This phenomenon was first described 
by Otto Heinrich Warburg, and is known as the Warburg effect [156]. While mitochondrial glucose 
oxidation generates 36 molecules of ATP per molecule of glucose, only two molecules of ATP are 
produced per molecule of glucose by aerobic breakdown. Cancer cells compensate for this by increasing 
the uptake of glucose and by stimulating the transcription of almost all the glycolytic enzymes in the 
cytoplasm [79,157,158]. Metabolism in Merkel cells and (MCPyV-positive) MCC has not been studied, 
but a Positron Emission Tomography (PET) scan of MCC with glucose analogues suggests a high rate 
of glycolysis in these tumors [159]. However, a possible role for MCPyV in enhanced glucose 
metabolism in MCC remains to be determined. Several studies with polyomavirus-transformed cells 
indicate that these viruses may affect glucose metabolism. Additionally, a redistribution of membrane 
glucose transporters, increased aerobic glycolysis and an increased activity of glycolytic enzymes were 
observed in SV40-transformed cells compared to non-transformed cells [160–162]. A role for  
JCPyV LT-ag in regulating the metabolic utilization of glucose in brain tumors has been recently 
suggested [163]. Another study showed that JCPyV LT-ag expressing medulloblastoma cells had a 
significantly lower mitochondrial respiration and glycolysis, but a three-fold higher consumption of 
glutamine compared to non-LT-ag expressing cells [164]. Oxygen consumption and glucose uptake were 
compared in fibroblast transduced with the telomerase catalytic subunit, or in combination with SV40 
LT-ag or LT-ag plus st-ag. A progressive increase in both metabolic markers was measured, as cell lines 
expressed more oncogenes. This observation underscores a role for LT-ag and st-ag in decreasing the 
cell’s dependence on mitochondrial energy production [165]. SV40 st-ag can activate Akt, while Akt 
can stimulate the expression of glycolytic enzymes and aerobic glycolysis [166–168]. SV40 st-ag can 
also activate the MEK/ERK mitogen-activated protein kinase pathway, which can then increase glucose 
transport [169,170]. These findings suggest that st-ag may stimulate glucose uptake and aerobic 
glycolysis. The tumor suppressor p53 acts as an anti-Warburg molecule because it acts as a potent 
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inhibitor of glycolysis [171]. The LT-ag of BKPyV and JCPyV has been shown to bind and inactivate 
p53 [172,173]. Although the LT-ag-mediated inactivation of p53 may promote glucose uptake and 
stimulate the glycolytic pathway, it may not be operational in MCPyV-positive MCC because the 
truncated form of LT-ag expressed in Merkel cell carcinomas does not bind p53 [40]. The interaction 
between p53 and LT-ag of other HPyV has not been investigated, but they all encompass a putative  
p53-binding motif [6]. 
Autophagy is another mechanism that allows cancer cells to maintain the levels of nutrients and 
energy in nutrient-limited environments, which helps to facilitate the survival of tumor cells. Moreover, 
autophagy regulates cellular invasion and metastasis [173]. The human tumor viruses EBV, KSHV, 
HBV, and HCV can modulate the autophagy pathway to favor viral infection by enhancing viral 
replication, prevent apoptosis or maintain a persistent and life-long infection [174]. Hence, viral 
interference with the autophagy pathway may contribute to tumorigenesis by these viruses, though less 
is known about the effect of HPyV on autophagy and the biological consequences. Bouley et al. could 
establish a supporting role for autophagy in BKPyV infection [175]. Using transformed human foreskin 
fibroblasts and HEK cells expressing or lacking the SV40 st-ag, it was demonstrated that st-ag helps to 
maintain energy homeostasis in glucose-deprivation cancer cells by activating AMP-activated protein 
kinase (AMPK), thereby inhibiting the mammalian target of rapamycin (mTOR) to shut down protein 
translation, and inducing autophagy as an alternate energy source. This protective role of st-ag under 
conditions of glucose deprivation depends on its ability to interact with protein phosphatase  
2A [176]. It is not known whether the st-ag of other HPyV may exert similar functions, but BKPyV, 
JCPyV, MCPyV and MWPyV (HPyV10) st-ag have also been shown to interact with PP2A [99,177–181]. 
Other effects of HPyV on autophagy came from a study by Khalili et al., who found that JCPyV LT-ag 
suppressed the expression of Bcl-2-associated athanogene Bag3, a protein implicated in apoptosis and 
autophagy [182]. On the other hand, overexpression of Bag3 induces autophagy-mediated degradation 
of JCPyV LT-ag. Bag3 interacts with the C-terminal half region of LT-ag which encompasses a zinc 
finger structure and partially overlaps with the p53 binding domain [183]. Consequently, LT-ag may 
repress the expression of Bag3 and protect itself from being degraded by Bag3-mediated autophagy. 
MCPyV-positive MCCs express C-terminal truncated LT-ag, which may impede interaction with Bag3. 
Under stress conditions, primary neuroglial cells immortalized with SV40 LT-ag had increased levels of 
the autophagy marker LC3B compared to non-LT-ag expressing cells [184]. However, the biological 
implication was not investigated. 
3.4. HPyV and Exosomes  
Exosomes are endosome-derived membrane vesicles of approximately 50 nm–100 nm in diameter 
that are shed by cells and act as a communication tool between cells. Exosomes contain cellular proteins, 
carbohydrates, lipids, DNA, rRNA, mRNA, siRNA and other non-coding RNAs (for recent reviews,  
see [185–187]). Exosomes secreted by tumor cells participate in the modulation of angiogenesis,  
cell proliferation, cell invasion, gene regulation and immune evasion, thereby creating advantages for 
malignant growth [186]. Exosomes released by virus-infected cells can also contain viral-derived 
components and are implicated in the pathogenesis of viruses. Indeed, the human oncoviruses Epstein-Barr 
virus, Kaposi sarcoma-associated herpes virus, hepatitis B virus, hepatitis C virus and human  
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T-lymphotropic virus type 1 all utilize exosomes to transfer viral (onco)proteins, mRNA and miRNAs 
to non-infected cells [188–194]. Exosomes captured by target cells may facilitate the spread of 
(onco)viral proteins and nucleic acids, thereby promoting malignancy in the recipient cells in the absence 
of an infection by virions. Exosomes can provoke immune alterations that may play a role to create an 
immunotolerogenic microenvironment during the carcinogenesis process. They can promote host 
immune and inflammatory responses by activating T- and B-cells, and by releasing exosome-trapped 
inflammatory molecules such as TNFα and IL1β in the recipient cells. Even so, exosomes have also been 
shown to inhibit immune responses by preventing CD4+ T-cell proliferation, CD8+ CTL response or 
transporting anti-inflammatory molecules (reviewed in [187]). 
The generation of exosomes by HPyV-infected cells has scarcely been investigated. Studies with 
mouse primitive glioblastoma-like brain tumor cell lines harbouring integrated SV40 large T-antigen 
DNA revealed the presence of SV40 large T-antigen sequences in exosomes produced by these  
cells [195]. Recently, JCPyV microRNA was detected in exosomes derived from human plasma and 
urine [196], although studies on the possible roles of exosomes released by HPyV-infected hosts cells 
are lacking. 
4. Therapeutic Strategies against Emerging Hallmarks of Cancer 
Specific inhibitors against HPyV are lacking, and the development of vaccines and vaccination are 
still in a very preliminary phase [197–201]. Therapeutic strategies directed against emerging features of 
cancer such as inflammation, immune evasion, exosomes, microRNA and energy homeostasis may offer 
alternatives to help combat HPyV-positive tumors. In vitro studies and MCC xenograft mouse models 
suggested a beneficial effect of IFN. Intratumoral administering of a mixture of different IFNα subtypes 
and IFNβ resulted in a regression of MCPyV-positive, but not MCPyV-negative xenografts of MCC 
cells, while IFNα-2b, IFNβ-1b, and IFNγ-1b challenge resulted in an increased cell-surface expression 
of MHC-I on MCC cell lines [96,202]. However, studies in patients with MCPyV-positive MCC have 
been proven to exhibit variable effects. Subcutaneous administration of IFN-β resulted in a complete 
regression of MCPyV-positive MCC tumors in a Japanese patient, but IFN-α-2b treatment of an  
84-year-old man and an 81-year-old woman had no effect [203,204]. IFNβ stimulated MHC-I expression 
on tumor cells of 3/3 MCPyV-positive MCC patients [96]. Intralesional treatment of a 67-year old 
MCPyV-positive MCC patient with INFβ-Ib, followed by re-infusion of expanded MCPyV  
LT-ag-specific CD8+ T-cells resulted in a complete response in two of three metastatic lesions and a 
delayed appearance of new metastasis compared to controls [205]. Tumor necrosis factor (TNF) can be 
considered as an alternative for treating MCC because this cytokine displayed a high efficacy in three 
patients [206,207], and in one patient out of three treated with IFNγ plus TNFα a complete response was 
noticed, while a partial and no response was observed in two others [208]. Because the three aforementioned 
TNFα studies were performed before the discovery of MCPyV, the presence of virus in the tumors was 
not known. Interestingly, patients who have been treated with TNFα inhibitors show an increased risk 
of developing MCC [209,210]. Another immunotherapy approach for the treatment of MCC could be 
PD-1 ligand and Tim-3, with these receptors highly expressed on MCPyV-specific CD+ T-cells. Drugs 
targeting the PD-1/PDL-1 pathway such as nivolumab (a blocking antibody against PD-1), 
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pembrolizumab (anti-PD-1 antibody) and BMS-936559 (anti-PDL-1 antibody) have been used in other 
cancers and may be used to treat MCC [211].  
Therapeutic strategies aimed at other emerging hallmarks of cancer have been little explored. 
Intratumoral delivery of anti-microRNA may help in silencing viral microRNA or viral-induced cellular 
microRNA, while RNA interference may turn off the expression of viral oncoproteins. RNA interference 
targeting LT-ag has been shown to abrogate HPyV replication in vitro and suppress tumor growth  
in vitro and in an animal model [180,212–217]. The use of exosomes as vaccines against cancer and 
infectious diseases has been suggested and exosomes pulsed with MCPyV LT-ag could be considered 
to treat MCPyV-positive MCC patients [187,218]. Lastly, therapeutic strategies directed against the 
metabolic changes in tumor cells (anti-glycolysis therapy) may be considered. The hexokinase inhibitor  
2-deoxyglucose inhibited growth of fibroblasts transformed by the telomerase catalytic subunit plus SV40 
LT-ag, and by the telomerase catalytic subunit plus SV40 LT-ag plus st-ag [165]. To our best knowledge, 
the effect of 2-deoxyglucose on the growth of MCPyV-positive MCC cells has not been investigated. 
5. Conclusion and Future Perspectives 
Seroprevalence studies demonstrate that HPyV viruses are common in the human population [36]. 
Although HPyV LT-ag and st-ag possess proven or putative transforming properties, only MCPyV 
seems to be associated with human cancer. This virus encodes additional early proteins (ALTO protein 
and 57 kD protein), whose functions are not completely understood [4,219]. Proper immune surveillance 
may explain why HPyVs establish a harmless life-long infection in most individuals, while immune 
deficiencies may lead to viral-associated pathologies, including malignancy. The role of HPyVs in the 
emerging hallmarks of cancer has been little investigated and further investigations are required to 
elucidate the mechanisms by which HPyV-positive tumors can evade the antiviral responses of the host 
and affect energy homeostasis. A better understanding of the tumor microenvironment is required to 
comprehend the development of MCC. A possible involvement of exosomes in HPyV-induced cancer 
and modulation of the immune system have not been addressed, and the role of viral microRNA or 
HPyV-induced microRNA in tumorigenesis is incompletely understood. Unveiling the mechanisms by 
which these viruses participate in emerging hallmarks of cancer may therefore enable the development 
of novel therapeutic strategies. 
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